Hamilton E - Search Results

1

Targeting HER2-positive breast cancer: advances and future directions.

Swain SM, Shastry M, Hamilton E. Swain SM, et al. Among authors: hamilton e. Nat Rev Drug Discov. 2023 Feb;22(2):101-126. doi: 10.1038/s41573-022-00579-0. Epub 2022 Nov 7. Nat Rev Drug Discov. 2023. PMID: 36344672 Free PMC article. Review.

2

Targeting CDK4/6 in patients with cancer.

Hamilton E, Infante JR. Hamilton E, et al. Cancer Treat Rev. 2016 Apr;45:129-38. doi: 10.1016/j.ctrv.2016.03.002. Epub 2016 Mar 8. Cancer Treat Rev. 2016. PMID: 27017286 Free article. Review.

3

Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR⁺/HER2^- Breast Cancer.

Sammons S, Shastry M, Dent S, Anders C, Hamilton E. Sammons S, et al. Among authors: hamilton e. Clin Breast Cancer. 2020 Feb;20(1):1-11. doi: 10.1016/j.clbc.2019.06.017. Epub 2019 Aug 23. Clin Breast Cancer. 2020. PMID: 31780379

4

Targeting HER2 heterogeneity in breast cancer.

Hamilton E, Shastry M, Shiller SM, Ren R. Hamilton E, et al. Cancer Treat Rev. 2021 Nov;100:102286. doi: 10.1016/j.ctrv.2021.102286. Epub 2021 Sep 2. Cancer Treat Rev. 2021. PMID: 34534820 Review.

5

Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics.

Sturgill EG, Misch A, Lachs R, Jones CC, Schlauch D, Jones SF, Shastry M, Yardley DA, Burris HA 3rd, Spigel DR, Hamilton EP, McKenzie AJ. Sturgill EG, et al. JCO Precis Oncol. 2021 Nov;5:1297-1311. doi: 10.1200/PO.20.00469. JCO Precis Oncol. 2021. PMID: 34994634

6

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.

Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA, Reeves J, Pan P, Shan M, Tang Y, Graham JR, Hazard S, Ellisen LW, Isakoff SJ. Spring LM, et al. Among authors: hamilton e. Nat Cancer. 2022 Aug;3(8):927-931. doi: 10.1038/s43018-022-00400-2. Epub 2022 Jul 4. Nat Cancer. 2022. PMID: 35788722 Free PMC article.

7

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.

Shastry M, Jacob S, Rugo HS, Hamilton E. Shastry M, et al. Among authors: hamilton e. Breast. 2022 Dec;66:169-177. doi: 10.1016/j.breast.2022.10.007. Epub 2022 Oct 18. Breast. 2022. PMID: 36302269 Free PMC article. Clinical Trial.

8

Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer.

Hamilton EP. Hamilton EP. Clin Adv Hematol Oncol. 2023 Mar;21(3):125-127. Clin Adv Hematol Oncol. 2023. PMID: 36867554 No abstract available.

9

Novel Estrogen Receptor-Targeted Agents for Breast Cancer.

Shastry M, Hamilton E. Shastry M, et al. Among authors: hamilton e. Curr Treat Options Oncol. 2023 Jul;24(7):821-844. doi: 10.1007/s11864-023-01079-y. Epub 2023 May 2. Curr Treat Options Oncol. 2023. PMID: 37129836 Review.

10

Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?

Corti C, De Angelis C, Bianchini G, Malorni L, Giuliano M, Hamilton E, Jeselsohn R, Jhaveri K, Curigliano G, Criscitiello C. Corti C, et al. Among authors: hamilton e. Cancer Treat Rev. 2023 Jun;117:102569. doi: 10.1016/j.ctrv.2023.102569. Epub 2023 Apr 28. Cancer Treat Rev. 2023. PMID: 37146385 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

987 results

Search Page